51 related articles for article (PubMed ID: 38765008)
21. Immunotherapy for sarcomas: new frontiers and unveiled opportunities.
Birdi HK; Jirovec A; Cortés-Kaplan S; Werier J; Nessim C; Diallo JS; Ardolino M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526607
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
Siozopoulou V; Domen A; Zwaenepoel K; Van Beeck A; Smits E; Pauwels P; Marcq E
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33478080
[TBL] [Abstract][Full Text] [Related]
23. An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.
Zekri L; Vogt F; Osburg L; Müller S; Kauer J; Manz T; Pflügler M; Maurer A; Heitmann JS; Hagelstein I; Märklin M; Hörner S; Todenhöfer T; Calaminus C; Stenzl A; Pichler B; la Fougère C; Schneider MA; Rammensee HG; Zender L; Sipos B; Salih HR; Jung G
EMBO Mol Med; 2021 Feb; 13(2):e11902. PubMed ID: 33372710
[TBL] [Abstract][Full Text] [Related]
24. Sarcoma treatment in the era of molecular medicine.
Grünewald TG; Alonso M; Avnet S; Banito A; Burdach S; Cidre-Aranaz F; Di Pompo G; Distel M; Dorado-Garcia H; Garcia-Castro J; González-González L; Grigoriadis AE; Kasan M; Koelsche C; Krumbholz M; Lecanda F; Lemma S; Longo DL; Madrigal-Esquivel C; Morales-Molina Á; Musa J; Ohmura S; Ory B; Pereira-Silva M; Perut F; Rodriguez R; Seeling C; Al Shaaili N; Shaabani S; Shiavone K; Sinha S; Tomazou EM; Trautmann M; Vela M; Versleijen-Jonkers YM; Visgauss J; Zalacain M; Schober SJ; Lissat A; English WR; Baldini N; Heymann D
EMBO Mol Med; 2020 Nov; 12(11):e11131. PubMed ID: 33047515
[TBL] [Abstract][Full Text] [Related]
25. Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years.
Lochner J; Menge F; Vassos N; Hohenberger P; Kasper B
Oncol Res Treat; 2020; 43(11):613-619. PubMed ID: 32854101
[TBL] [Abstract][Full Text] [Related]
26. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Yang S; Wei W; Zhao Q
Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
[TBL] [Abstract][Full Text] [Related]
27. Memory T cell, exhaustion, and tumor immunity.
Ando M; Ito M; Srirat T; Kondo T; Yoshimura A
Immunol Med; 2020 Mar; 43(1):1-9. PubMed ID: 31822213
[TBL] [Abstract][Full Text] [Related]
28. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S; Bielack SS; Whelan J; Bernstein M; Hogendoorn P; Krailo MD; Gorlick R; Janeway KA; Ingleby FC; Anninga J; Antal I; Arndt C; Brown KLB; Butterfass-Bahloul T; Calaminus G; Capra M; Dhooge C; Eriksson M; Flanagan AM; Friedel G; Gebhardt MC; Gelderblom H; Goldsby R; Grier HE; Grimer R; Hawkins DS; Hecker-Nolting S; Sundby Hall K; Isakoff MS; Jovic G; Kühne T; Kager L; von Kalle T; Kabickova E; Lang S; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Mayer-Steinacker R; Meyers PA; Nagarajan R; Randall RL; Reichardt P; Renard M; Rechnitzer C; Schwartz CL; Strauss S; Teot L; Timmermann B; Sydes MR; Marina N
Eur J Cancer; 2019 Mar; 109():36-50. PubMed ID: 30685685
[TBL] [Abstract][Full Text] [Related]
29. Options for treating different soft tissue sarcoma subtypes.
Ray-Coquard I; Serre D; Reichardt P; Martín-Broto J; Bauer S
Future Oncol; 2018 May; 14(10s):25-49. PubMed ID: 29768052
[TBL] [Abstract][Full Text] [Related]
30. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany.
Ressing M; Wardelmann E; Hohenberger P; Jakob J; Kasper B; Emrich K; Eberle A; Blettner M; Zeissig SR
BMC Public Health; 2018 Feb; 18(1):235. PubMed ID: 29433465
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis.
Zhang X; Fang C; Zhang G; Jiang F; Wang L; Hou J
Oncotarget; 2017 Nov; 8(54):93156-93167. PubMed ID: 29190985
[TBL] [Abstract][Full Text] [Related]
33. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
[TBL] [Abstract][Full Text] [Related]
34. Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
Seaman S; Zhu Z; Saha S; Zhang XM; Yang MY; Hilton MB; Morris K; Szot C; Morris H; Swing DA; Tessarollo L; Smith SW; Degrado S; Borkin D; Jain N; Scheiermann J; Feng Y; Wang Y; Li J; Welsch D; DeCrescenzo G; Chaudhary A; Zudaire E; Klarmann KD; Keller JR; Dimitrov DS; St Croix B
Cancer Cell; 2017 Apr; 31(4):501-515.e8. PubMed ID: 28399408
[TBL] [Abstract][Full Text] [Related]
35. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.
Savina M; Le Cesne A; Blay JY; Ray-Coquard I; Mir O; Toulmonde M; Cousin S; Terrier P; Ranchere-Vince D; Meeus P; Stoeckle E; Honoré C; Sargos P; Sunyach MP; Le Péchoux C; Giraud A; Bellera C; Le Loarer F; Italiano A
BMC Med; 2017 Apr; 15(1):78. PubMed ID: 28391775
[TBL] [Abstract][Full Text] [Related]
36. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.
Golubovskaya V; Wu L
Cancers (Basel); 2016 Mar; 8(3):. PubMed ID: 26999211
[TBL] [Abstract][Full Text] [Related]
37. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
[TBL] [Abstract][Full Text] [Related]
38. Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice.
Yin SJ; Wang WJ; Zhang JY
Genet Mol Res; 2015 Nov; 14(4):14253-61. PubMed ID: 26600483
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database.
Duchman KR; Gao Y; Miller BJ
Cancer Epidemiol; 2015 Aug; 39(4):593-9. PubMed ID: 26002013
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of B7-H3 in CD133+ colorectal cancer cells is associated with cancer progression and survival in human patients.
Bin Z; Guangbo Z; Yan G; Huan Z; Desheng L; Xueguang Z
J Surg Res; 2014 May; 188(2):396-403. PubMed ID: 24630518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
